Conversely, LINC00641 has been studied and reported as a tumor inhibitor in many cancers, including prostate cancer (29), bladder cancer (30), renal cancer (31), cervical cancer (32), non-small-cell lung cancer (33) and breast cancer (34). Here, LINC00641 is linked to renal carcinoma.